| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f0720c9589ac003eef11dd5e3fdb3886 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-186 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337 |
| filingDate |
2018-01-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_336e2e93e17f8a4c5bcb1a5e123acadb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c42cbbee91b55baccb64bae4527fc535
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c62473ef107bab0e0b4fb37359b00a48 |
| publicationDate |
2019-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3565530-A1 |
| titleOfInvention |
Treatment of pancreatic cancer |
| abstract |
A method of treating refractory or resistant pancreatic cancer by administering: (i) a cationic liposomal formulation comprising one or more cationic lipids and a therapeutically effective amount of paclitaxel; or (ii) a cationic liposomal formulation comprising one or more cationic lipids and a therapeutically effective amount of paclitaxel, and a therapeutically effective amount of gemcitabine. |
| priorityDate |
2017-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |